225 related articles for article (PubMed ID: 31274560)
1. Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin αvβ3.
Zheng Y; Wang H; Tan H; Cui X; Yao S; Zang J; Zhang L; Zhu Z
Clin Nucl Med; 2019 Sep; 44(9):687-694. PubMed ID: 31274560
[TBL] [Abstract][Full Text] [Related]
2. A prospective head-to-head comparison of
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
[TBL] [Abstract][Full Text] [Related]
3. Inter-heterogeneity and intra-heterogeneity of α
Kang F; Wang Z; Li G; Wang S; Liu D; Zhang M; Zhao M; Yang W; Wang J
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1520-1528. PubMed ID: 28405726
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of a dual sstr2 and integrin α
Liu B; Zhang Z; Wang H; Yao S
Bioorg Med Chem; 2019 Nov; 27(21):115094. PubMed ID: 31540828
[TBL] [Abstract][Full Text] [Related]
5. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
8. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting PET tracer [
Wang R; Jakobsson V; Wang J; Zhao T; Peng X; Li B; Xue J; Liang N; Zhu Z; Chen X; Zhang J
Theranostics; 2023; 13(9):2979-2992. PubMed ID: 37284441
[No Abstract] [Full Text] [Related]
10. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
11. The added value of
Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC
Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
[TBL] [Abstract][Full Text] [Related]
12. A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients.
Gao S; Wu H; Li W; Zhao S; Teng X; Lu H; Hu X; Wang S; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2029-37. PubMed ID: 26153145
[TBL] [Abstract][Full Text] [Related]
13. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
14.
Zhang J; Mao F; Niu G; Peng L; Lang L; Li F; Ying H; Wu H; Pan B; Zhu Z; Chen X
Theranostics; 2018; 8(4):1121-1130. PubMed ID: 29464003
[No Abstract] [Full Text] [Related]
15. Integrin Imaging with
Jin X; Liang N; Wang M; Meng Y; Jia B; Shi X; Li S; Luo J; Luo Y; Cui Q; Zheng K; Liu Z; Shi J; Li F; Wang F; Zhu Z
Radiology; 2016 Dec; 281(3):958-966. PubMed ID: 27479638
[TBL] [Abstract][Full Text] [Related]
16. 3p-C-NETA: A versatile and effective chelator for development of Al
Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F
Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589
[No Abstract] [Full Text] [Related]
17.
Chen CJ; Chan CH; Lin KL; Chen JH; Tseng CH; Wang PY; Chien CY; Yu HM; Lin WJ
Nucl Med Biol; 2019; 68-69():22-30. PubMed ID: 30578136
[TBL] [Abstract][Full Text] [Related]
18. PET/CT Imaging of NSCLC with a α
Flechsig P; Lindner T; Loktev A; Roesch S; Mier W; Sauter M; Meister M; Herold-Mende C; Haberkorn U; Altmann A
Mol Imaging Biol; 2019 Oct; 21(5):973-983. PubMed ID: 30671741
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer.
Zheng K; Liang N; Zhang J; Lang L; Zhang W; Li S; Zhao J; Niu G; Li F; Zhu Z; Chen X
J Nucl Med; 2015 Dec; 56(12):1823-7. PubMed ID: 26429958
[TBL] [Abstract][Full Text] [Related]
20. (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging.
Liu Z; Niu G; Wang F; Chen X
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1483-94. PubMed ID: 19360404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
